Jazz Pharmaceuticals plc Common Stock (Ireland) JAZZ
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T02:46:05.682Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:00:08.508643415Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T02:46:05.669060+00:00
Jazz Pharmaceuticals plc Common Stock (Ireland) options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 254.33 | 40.8% | 6.5% | 231.20 | 31.1% | 4.4% |
| 25Δ | 251.00 | 39.8% | 5.3% | 232.84 | 30.2% | 3.8% |
| 30Δ | 248.68 | 38.7% | 4.5% | 234.49 | 29.3% | 3.3% |
| 35Δ | 246.79 | 37.6% | 4.0% | 236.13 | 28.4% | 2.8% |
| 40Δ | 244.89 | 36.5% | 3.4% | 237.78 | 27.5% | 2.3% |
| 45Δ | 243.00 | 35.3% | 2.8% | 239.42 | 26.6% | 1.8% |
| 50Δ | 241.11 | 34.2% | 2.3% | 240.85 | 26.2% | 1.5% |
| 55Δ | 239.29 | 33.6% | 1.8% | 242.17 | 26.0% | 1.3% |
| 60Δ | 237.59 | 33.6% | 1.6% | 243.48 | 25.8% | 1.1% |
| 65Δ | 235.88 | 33.6% | 1.4% | 244.80 | 25.6% | 0.9% |
| 70Δ | 234.17 | 33.7% | 1.1% | 246.11 | 25.4% | 0.7% |
| 75Δ | 232.47 | 33.7% | 0.9% | 247.43 | 25.2% | 0.6% |
| 80Δ | 230.76 | 33.8% | 0.7% | 248.74 | 25.0% | 0.4% |
20Δ
- Pseudo strike
- 254.33
- IV
- 40.8%
- B/E move
- 6.5%
- Pseudo strike
- 231.20
- IV
- 31.1%
- B/E move
- 4.4%
25Δ
- Pseudo strike
- 251.00
- IV
- 39.8%
- B/E move
- 5.3%
- Pseudo strike
- 232.84
- IV
- 30.2%
- B/E move
- 3.8%
30Δ
- Pseudo strike
- 248.68
- IV
- 38.7%
- B/E move
- 4.5%
- Pseudo strike
- 234.49
- IV
- 29.3%
- B/E move
- 3.3%
35Δ
- Pseudo strike
- 246.79
- IV
- 37.6%
- B/E move
- 4.0%
- Pseudo strike
- 236.13
- IV
- 28.4%
- B/E move
- 2.8%
40Δ
- Pseudo strike
- 244.89
- IV
- 36.5%
- B/E move
- 3.4%
- Pseudo strike
- 237.78
- IV
- 27.5%
- B/E move
- 2.3%
45Δ
- Pseudo strike
- 243.00
- IV
- 35.3%
- B/E move
- 2.8%
- Pseudo strike
- 239.42
- IV
- 26.6%
- B/E move
- 1.8%
50Δ
- Pseudo strike
- 241.11
- IV
- 34.2%
- B/E move
- 2.3%
- Pseudo strike
- 240.85
- IV
- 26.2%
- B/E move
- 1.5%
55Δ
- Pseudo strike
- 239.29
- IV
- 33.6%
- B/E move
- 1.8%
- Pseudo strike
- 242.17
- IV
- 26.0%
- B/E move
- 1.3%
60Δ
- Pseudo strike
- 237.59
- IV
- 33.6%
- B/E move
- 1.6%
- Pseudo strike
- 243.48
- IV
- 25.8%
- B/E move
- 1.1%
65Δ
- Pseudo strike
- 235.88
- IV
- 33.6%
- B/E move
- 1.4%
- Pseudo strike
- 244.80
- IV
- 25.6%
- B/E move
- 0.9%
70Δ
- Pseudo strike
- 234.17
- IV
- 33.7%
- B/E move
- 1.1%
- Pseudo strike
- 246.11
- IV
- 25.4%
- B/E move
- 0.7%
75Δ
- Pseudo strike
- 232.47
- IV
- 33.7%
- B/E move
- 0.9%
- Pseudo strike
- 247.43
- IV
- 25.2%
- B/E move
- 0.6%
80Δ
- Pseudo strike
- 230.76
- IV
- 33.8%
- B/E move
- 0.7%
- Pseudo strike
- 248.74
- IV
- 25.0%
- B/E move
- 0.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 35.67% | |
| 36.64% | |
| 37.53% | |
| 38.13% | |
| 44.54% | |
| 37.88% | |
| 39.18% | |
| 32.28% | |
| 30.90% | |
| 30.29% | |
| 30.44% | |
| 27.76% | |
| 28.24% | |
| 27.90% | |
| 27.83% | |
| 28.04% | |
| 29.41% | |
| 29.88% | |
| 28.59% | |
| 28.96% | |
| 30.64% | |
| 28.47% | |
| 29.06% | |
| 28.57% | |
| 28.57% | |
| 29.09% | |
| 28.38% | |
| 28.77% | |
| 28.53% | |
| 29.91% | |
| 29.16% | |
| 28.79% | |
| 28.16% | |
| 29.58% | |
| 29.87% | |
| 30.30% | |
| 29.84% | |
| 32.13% | |
| 33.06% | |
| 32.67% | |
| 32.73% | |
| 33.28% | |
| 33.37% | |
| 33.25% | |
| 34.57% | |
| 34.96% | |
| 35.53% | |
| 36.27% | |
| 36.48% | |
| 36.65% | |
| 38.91% |
Biotechnology
JBIO
Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company is…
More →JSPR
Description unavailable
More →KARD
Kardigan, Inc. is an innovative technology company specializing in advanced software solutions for retail and e-commerce industries. With a strong focus on enhancing customer…
More →KLRA
Description unavailable
More →KOD
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States…
More →KPTI
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and…
More →